• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

POLL: Which Recent Drug Pipeline Move is Most Exciting?

Poll

Click here to answer this week's poll.

Many drug treatments have made pipeline moves in the last few weeks. Which one do you think is the most exciting?

Apremilast (Otezla; Amgen) receiving FDA approval for all psoriasis severities
Secukinumab (Cosentyx; Novartis) FDA approval for pediatric patients with PsA
Tralokinumab-Idrm (Adbry; Leo Pharma) receives FDA approval for AD
Roflumilast Cream (ARQ-151; Arcutis Biotherapeutics) has NDA accepted by FDA for psoriasis treatment
Something Else
Related Videos
infectious disease
Related Content
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Article
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Podcast
MoonLake Immunotherapeutics and Komodo Health to Partner to Improve Research on Inflammatory Skin Conditions

MoonLake Immunotherapeutics and Komodo Health to Partner to Improve Research on Inflammatory Skin Conditions

Article
The Cutaneous Connection

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

Podcast
Pelthos Therapeutics Launches to Accelerate Commercialization of Treatment for Molluscum Contagiosum

Pelthos Therapeutics Launches to Accelerate Commercialization of Treatment for Molluscum Contagiosum

Article
ARCA Biopharma and Oruka Therapeutics Agree to Merger

ARCA Biopharma and Oruka Therapeutics Agree to Merger

Article
© 2024 MJH Life Sciences

All rights reserved.